Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Citigroup

Citigroup upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) to a hold rating in a research report released on Wednesday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. cut their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Wells Fargo & Company decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One analyst has rated the stock with a sell rating, four have given a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Trading Down 3.3 %

Shares of REGN stock opened at $756.81 on Wednesday. The company has a market cap of $83.17 billion, a P/E ratio of 18.93, a PEG ratio of 3.04 and a beta of 0.15. Regeneron Pharmaceuticals has a fifty-two week low of $753.69 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a 50 day simple moving average of $992.70 and a two-hundred day simple moving average of $1,033.92.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 7.48% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Vestcor Inc lifted its stake in Regeneron Pharmaceuticals by 3.1% in the third quarter. Vestcor Inc now owns 21,590 shares of the biopharmaceutical company’s stock worth $22,696,000 after acquiring an additional 654 shares during the period. M&T Bank Corp increased its position in shares of Regeneron Pharmaceuticals by 4.3% during the third quarter. M&T Bank Corp now owns 5,480 shares of the biopharmaceutical company’s stock valued at $5,761,000 after buying an additional 224 shares during the period. Groupama Asset Managment raised its stake in Regeneron Pharmaceuticals by 7.0% in the third quarter. Groupama Asset Managment now owns 71,277 shares of the biopharmaceutical company’s stock worth $74,929,000 after buying an additional 4,648 shares in the last quarter. Nomura Asset Management Co. Ltd. boosted its position in Regeneron Pharmaceuticals by 4.5% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 86,004 shares of the biopharmaceutical company’s stock valued at $90,411,000 after acquiring an additional 3,698 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $9,908,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.